AU2002241547A1 - Mch antagonists and their use in the treatment of obesity - Google Patents

Mch antagonists and their use in the treatment of obesity

Info

Publication number
AU2002241547A1
AU2002241547A1 AU2002241547A AU2002241547A AU2002241547A1 AU 2002241547 A1 AU2002241547 A1 AU 2002241547A1 AU 2002241547 A AU2002241547 A AU 2002241547A AU 2002241547 A AU2002241547 A AU 2002241547A AU 2002241547 A1 AU2002241547 A1 AU 2002241547A1
Authority
AU
Australia
Prior art keywords
obesity
treatment
mch antagonists
mch
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002241547A
Inventor
John Clader
Mark D. Mc Briar
Anandan Palani
Sherry A. Shapiro
Ruo Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2002241547A1 publication Critical patent/AU2002241547A1/en
Abandoned legal-status Critical Current

Links

AU2002241547A 2000-12-01 2001-11-29 Mch antagonists and their use in the treatment of obesity Abandoned AU2002241547A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60/250,502 2000-12-01

Publications (1)

Publication Number Publication Date
AU2002241547A1 true AU2002241547A1 (en) 2002-07-30

Family

ID=

Similar Documents

Publication Publication Date Title
HK1054225A1 (en) Mch antagonists and their use in the treatment of obesity
IL157365A0 (en) Mch antagonists and their use in the treatment of obesity
IL155772A0 (en) Piperidine mch antagonists and their use in the treatment of obesity
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU2003291609A1 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
HUP0301417A2 (en) Antimikrobal and contraceptive composition and their use
EP1487492A4 (en) The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
HUP0400069A3 (en) Pharmaceutical combinations and their use in preventing and treating the thrombosis
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU2002366201A1 (en) Use of defined copolymers as adjuvants and agents in the agrotechnical domain
AU2002252976A1 (en) Hydrazones and their therapeutic use
IL159872A0 (en) Gmg-2 polypeptides and their use
EP1558238A4 (en) Beta-hydroxyphenylaldylamines and their use for treating glaucoma
AU2001252132A1 (en) Substituted 5-methyldihydropyridazinones and their use in the prophylaxis and/ortreatment of anemias
AU2002346288A1 (en) Plypropylene fabric and its use in the personal care field
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
AU2002241547A1 (en) Mch antagonists and their use in the treatment of obesity
EP1367123A4 (en) Neurotonin and use thereof
AU6330300A (en) Use of interleukin-6 in treatment of obesity and/or obesity associated disorders
EP1392460A4 (en) Hydrogenfluorides of aminosilanols and their use
AU2002220626A1 (en) 3-nitroisoxazoles and their use in the protection of materials
GB0200843D0 (en) Benzodioxinopyrroles their preparation and use
AU5104101A (en) Composition and use
GB0015623D0 (en) Phosphoglycan messengers and their medical uses